Cargando…

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis

Early endpoints, such as progression-free survival (PFS), are increasingly used as surrogates for overall survival (OS) to accelerate approval of novel oncology agents. Compiling trial-level data from randomized controlled trials (RCTs) could help to develop a predictive framework to ascertain corre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shameer, Khader, Zhang, Youyi, Jackson, Dan, Rhodes, Kirsty, Neelufer, Imran Khan A., Nampally, Sreenath, Prokop, Andrzej, Hutchison, Emmette, Ye, Jiabu, Malkov, Vladislav A., Liu, Feng, Sabin, Antony, Weatherall, Jim, Duran, Cristina, Iacona, Renee Bailey, Khan, Faisal M., Mukhopadhyay, Pralay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351517/ https://www.ncbi.nlm.nih.gov/pubmed/34381708 http://dx.doi.org/10.3389/fonc.2021.672916

Ejemplares similares

OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non–Small-Cell Lung Cancer Clinical Trials
por: Shameer, Khader, et al.
Publicado: (2022)

Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
por: Ye, Jiabu, et al.
Publicado: (2020)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

Eating less suppresses microRNA assassins in the brain
por: Hutchison, Emmette, et al.
Publicado: (2011)

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis
por: Mukhopadhyay, Pralay, et al.
Publicado: (2022)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
por: Ouwens, Mario J. N. M., et al.
Publicado: (2019)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Correction to: The role of machine learning in clinical research: transforming the future of evidence generation
por: Weissler, E. Hope, et al.
Publicado: (2021)

The role of machine learning in clinical research: transforming the future of evidence generation
por: Weissler, E. Hope, et al.
Publicado: (2021)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study
por: Ouwens, Mario, et al.
Publicado: (2021)

Bayesian forecasting of tumor size metrics and overall survival
por: Krishnan, Sreenath M., et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

IWS: Integrated web server for protein sequence and structure analysis
por: Shameer, Khader, et al.
Publicado: (2007)

Functional repertoire, molecular pathways and diseases associated with 3D domain swapping in the human proteome
por: Shameer, Khader, et al.
Publicado: (2012)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
por: Zheng, Yanan, et al.
Publicado: (2018)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

The Keynesian Endpoint
por: Crescenzi, Tony
Publicado: (2010)

Endpoint security
por: Kadrich, Mark
Publicado: (2007)

OPERA models for predicting physicochemical properties and environmental fate endpoints
por: Mansouri, Kamel, et al.
Publicado: (2018)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival
por: Kurumaddali, Abhinav, et al.
Publicado: (2019)

A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
por: Cooper, Katy, et al.
Publicado: (2020)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_i91pqb5n93lpbhlndq911ffhla